<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">WJCR</journal-id><journal-title-group><journal-title>World Journal of Cancer Research</journal-title></journal-title-group><issn pub-type="epub">2164-9049</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/WJCR.2018.82013</article-id><article-id pub-id-type="publisher-id">WJCR-24725</article-id><article-categories><subj-group subj-group-type="heading"><subject>WJCR20180200000_52840972.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  LRRC超家族成员在肿瘤的研究进展
  The Progress of Research on LRRC Super Family Members in Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>史</surname><given-names>婧怡</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>妍珂</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>西安交通大学医学部，陕西 西安 </addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>sjy1995@stu.xjtu.edu.cn(史婧)</email>;<email>paincyk@xjtu.edu.cn(陈妍)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>11</day><month>04</month><year>2018</year></pub-date><volume>08</volume><issue>02</issue><fpage>81</fpage><lpage>85</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   富亮氨酸重复序列(LRR)存在于多种蛋白质中，介导多种蛋白与蛋白之间的相互作用。近年来一些研究发现：LRRC超家族成员LRRC4、LRRC3B和LG11在多种肿瘤组织表达缺失或显著降低，并具有抑癌基因的功能；而另外一些LRRC超家族成员LGR4和LGR5在肿瘤中高表达，表现出原癌基因的作用。以上研究提示它们可能成为肿瘤诊断和治疗的新靶点。本文就LRRC超家族成员在肿瘤的研究进展进行回顾性综述。 The leucine rich repeat sequence (LRR) domains are known to mediate protein-protein interactions. In recent years, some studies have found that members of the LRRC super family (for example LRRC4, LRRC3B and LG11) were absent or significantly down-expressed in a variety of tumor tissue, and have the potential of suppressing tumorigenesis and tumor cell proliferation. LGR4 and LGR5 are up-expression in tumor, and show the function of proto-oncogene. These findings suggested that members of the LRRC super family may become the new target for diagnosis and treatment of tumor. In the present review we summarize the current literature about LRRC super family in the cancer. 
  
 
</p></abstract><kwd-group><kwd>富亮氨酸重复序列(LRR)，肿瘤, Leucine Rich Repeat Sequence (LRR)</kwd><kwd> Cancer</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>LRRC超家族成员在肿瘤的研究进展<sup> </sup></title><p>史婧怡，陈妍珂<sup>*</sup></p><p>西安交通大学医学部，陕西 西安</p><disp-formula id="hanspub.24725-formula105"><graphic xlink:href="//html.hanspub.org/file/4-2150144x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2018年4月5日；录用日期：2018年4月23日；发布日期：2018年4月30日</p><disp-formula id="hanspub.24725-formula106"><graphic xlink:href="//html.hanspub.org/file/4-2150144x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>富亮氨酸重复序列(LRR)存在于多种蛋白质中，介导多种蛋白与蛋白之间的相互作用。近年来一些研究发现：LRRC超家族成员LRRC4、LRRC3B和LG11在多种肿瘤组织表达缺失或显著降低，并具有抑癌基因的功能；而另外一些LRRC超家族成员LGR4和LGR5在肿瘤中高表达，表现出原癌基因的作用。以上研究提示它们可能成为肿瘤诊断和治疗的新靶点。本文就LRRC超家族成员在肿瘤的研究进展进行回顾性综述。</p><p>关键词 :富亮氨酸重复序列(LRR)，肿瘤</p><disp-formula id="hanspub.24725-formula107"><graphic xlink:href="//html.hanspub.org/file/4-2150144x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2018 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/4-2150144x8_hanspub.png" /> <img src="//html.hanspub.org/file/4-2150144x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>富亮氨酸重复(1eucine rich repeat, LRR)序列存在于多种蛋白质中，1985年由Takahashi等从人血清糖蛋白中首次发现 [<xref ref-type="bibr" rid="hanspub.24725-ref1">1</xref>] ，因亮氨酸残基在该结构中呈规律性排列而将其命名为LRR。富含LRR基序的蛋白(Leucinerich repeat containing protein, LRRC)广泛分布于胞浆、胞膜、细胞核和细胞外基质中，组成了进化上保守、功能多样的LRRC超家族。目前发现其成员已多达4000多种，包括细胞黏附分子、核糖核酸酶抑制剂、酪氨酸激酶受体、细胞外基质糖蛋白及病毒因子等，它们参与生物体的多种功能，如细胞的黏附、极性分化及胞内转运、基因的表达调控、激素与受体的相互作用和神经系统的发育等 [<xref ref-type="bibr" rid="hanspub.24725-ref2">2</xref>] 。</p></sec><sec id="s4"><title>2. LRR基序的结构特征</title><p>该结构域通常由20~29个氨基酸残基组成，其中包含一段长度为11个残基的保守序列LxxLxLxxN/CxL，其中x代表任意氨基酸，L可以被缬氨酸、异亮氨酸或苯丙氨酸取代 [<xref ref-type="bibr" rid="hanspub.24725-ref3">3</xref>] 。Kobe和Deisenhofer研究发现，每个LRR基序由一个保守的β-片层和一个变化的α-螺旋通过loop环连接形成，相邻的多个LRR通常围绕共同的轴平行排列，形成一个卷曲的马蹄形结构。在这种结构中，β-片层与配体相结合形成一个疏水性核心，而α-螺旋则暴露在马蹄形结构的外周。当配体与受体结合时，其马蹄形结构发生改变 [<xref ref-type="bibr" rid="hanspub.24725-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.24725-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.24725-ref5">5</xref>] 。因此，LRR结构域介导多种蛋白与蛋白之间的相互作用。</p></sec><sec id="s5"><title>3. 具有抑癌基因性质的LRRC超家族成员</title><p>以往的研究发现：在头颈部肿瘤、乳腺癌、结直肠癌、卵巢癌及前列腺癌等多种恶性肿瘤中染色体7q31-32区和10q23-26区存在多个位点等位基因杂合性丢失(Loss of heterozygosity, LOH)和基因重排现象，提示该区域可能存在多个与恶性肿瘤发生和进展相关的基因 [<xref ref-type="bibr" rid="hanspub.24725-ref6">6</xref>] - [<xref ref-type="bibr" rid="hanspub.24725-ref11">11</xref>] 。王杰如等人运用EST介导的定位候选克隆技术从7q31-32区克隆出一个LRR超家族成员LRRC4 [<xref ref-type="bibr" rid="hanspub.24725-ref12">12</xref>] 。张秋红等人的研究发现LRRC4在正常人脑组织中特异性表达，而在多种原发性脑瘤中表达明显下调甚至缺失，且其表达水平与脑胶质瘤的病理分级密切负相关 [<xref ref-type="bibr" rid="hanspub.24725-ref13">13</xref>] 。在胶质母细胞瘤U251细胞过表达LRRC4显著抑制肿瘤细胞的成瘤能力和生长 [<xref ref-type="bibr" rid="hanspub.24725-ref14">14</xref>] 。LRRC4主要通过阻断ERK/MAPK信号通路，下调Cyclin E和Cyclin A周期素的表达，抑制CDK2激酶的活性，上调p21<sup>wafi/Cip1</sup>和p27<sup>Kip1</sup>的表达，将细胞周期阻断在G1期。同时，LRRC4通过抑制PCNA抑制DNA复制，最终抑制胶质瘤细胞的增殖和成瘤 [<xref ref-type="bibr" rid="hanspub.24725-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.24725-ref15">15</xref>] 。LRRC4还可以通过抑制SDF-1α/CXCR4生物学轴而减弱U251细胞的侵袭运动能力 [<xref ref-type="bibr" rid="hanspub.24725-ref16">16</xref>] 。LRR结构域缺失的突变体不再抑制U251细胞的生长和侵袭；而Ig2或Tm区缺失的突变体仍然可以抑制U251细胞的生长和侵袭。该结果表明，LRRC4抑制U251细胞的生长和侵袭依赖于它的LRR结构域，而不是IgC2或Tm结构域 [<xref ref-type="bibr" rid="hanspub.24725-ref15">15</xref>] 。</p><p>Chemova等人采用定位克隆技术也从染色体10q24区克隆到LRRC超家族另外一个成员LGll (1eucine-rich glioma inactivated1) [<xref ref-type="bibr" rid="hanspub.24725-ref11">11</xref>] 。研究发现，LGll主要分布于正常神经系统组织，在恶性胶质瘤中由于基因重排其表达明显下调甚至缺失 [<xref ref-type="bibr" rid="hanspub.24725-ref17">17</xref>] 。将LGll基因转入不表达内源性LGll的胶质瘤细胞系T98G和A172中，结果发现LGll基因的再表达显著抑制细胞的增殖和侵袭 [<xref ref-type="bibr" rid="hanspub.24725-ref18">18</xref>] 。通过人类癌症微阵列分层研究比较肿瘤组织与正常组织基因表达谱，一些研究发现LRRC超家族另一个成员LRRC3B在人类乳腺癌 [<xref ref-type="bibr" rid="hanspub.24725-ref19">19</xref>] 、胶质瘤 [<xref ref-type="bibr" rid="hanspub.24725-ref20">20</xref>] 、结肠癌 [<xref ref-type="bibr" rid="hanspub.24725-ref21">21</xref>] 、前列腺癌 [<xref ref-type="bibr" rid="hanspub.24725-ref22">22</xref>] 、胃癌 [<xref ref-type="bibr" rid="hanspub.24725-ref23">23</xref>] 及肺癌 [<xref ref-type="bibr" rid="hanspub.24725-ref24">24</xref>] 中表达显著下调。将LRRC3B过表达质粒转染至人胃癌细胞中，观察到LRRC3B可抑制癌细胞集落形成 [<xref ref-type="bibr" rid="hanspub.24725-ref25">25</xref>] 。</p><p>以上研究结果表明，部分LRRC超家族成员在肿瘤组织表达显著降低。究其原因，除了基因杂合性丢失和基因重排外，还可能与启动子区过度甲基化修饰有关。LRRC4的启动子在表达缺失的SFl26和SF767细胞存在完全的甲基化，采用去甲基化制剂5-Aza—CdR处理后，LRRC4表达显著上调 [<xref ref-type="bibr" rid="hanspub.24725-ref26">26</xref>] 。</p></sec><sec id="s6"><title>4. 具有原癌基因性质的LRRC家族成员</title><p>以上LRRC分子都表现出抑制肿瘤生长和侵袭的作用，由此可以推测LRRC超家族成员都具有抑癌基因的性质吗？最近几年，陆续有研究报道LRRC超家族成员在肿瘤中的作用不是如此简单。LGR4 (leucine-rich repeat domain containing G protein-coupled receptor 4)被发现在多种肿瘤中表达失调，它通过激活Jmjd2a/AR信号通路抑制前列腺癌细胞凋亡 [<xref ref-type="bibr" rid="hanspub.24725-ref27">27</xref>] 。LGR5也被报道在肝癌 [<xref ref-type="bibr" rid="hanspub.24725-ref28">28</xref>] 、胃癌 [<xref ref-type="bibr" rid="hanspub.24725-ref29">29</xref>] 、基底细胞癌 [<xref ref-type="bibr" rid="hanspub.24725-ref30">30</xref>] 、结肠癌和卵巢癌 [<xref ref-type="bibr" rid="hanspub.24725-ref31">31</xref>] 中表达升高。过表达LGR5促进肿瘤细胞增殖 [<xref ref-type="bibr" rid="hanspub.24725-ref30">30</xref>] ，而沉默其表达诱导肿瘤细胞凋亡 [<xref ref-type="bibr" rid="hanspub.24725-ref29">29</xref>] 。</p></sec><sec id="s7"><title>5. 小结和展望</title><p>综上所述，LRRC超家族成员在不同类型的恶性肿瘤中，其表达特点和作用都存在差异，提示LRRC超家族成员作用的复杂性。由于LRR结构域参与细胞内多种蛋白相互作用，因此推测LRRC超家族成员可能通过蛋白互作调控肿瘤细胞的生长和侵袭转移。深入研究该家族成员在肿瘤发生和进展中的作用和机制，有助于发展新的肿瘤标志物和靶向治疗分子，为肿瘤的诊断和治疗提供新的思路。</p></sec><sec id="s8"><title>致谢</title><p>陕西省国际科技合作与交流计划面上项目(编号：2017KW-059)和西安交通大学本科生创新实验资助项目(编号：XJ201610698177)资助。</p></sec><sec id="s9"><title>文章引用</title><p>史婧怡,陈妍珂. LRRC超家族成员在肿瘤的研究进展 The Progress of Research on LRRC Super Family Members in Cancer[J]. 世界肿瘤研究, 2018, 08(02): 81-85. https://doi.org/10.12677/WJCR.2018.82013</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.24725-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Takahashi, N., Takahashi, Y. and Putnam, F.W. (1985) Periodicity of Leucine and Tandem Repetition of a 24-Amino Acid Segment in the Primary Structure of Leucine-Rich Alpha 2-Glycoprotein of Human Serum. Proceedings of the National Academy of Sciences of the United States of America, 82, 1906-1910. https://doi.org/10.1073/pnas.82.7.1906</mixed-citation></ref><ref id="hanspub.24725-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">李丹, 李桂源. 富亮氨酸重复超家族成员与脑瘤的研究进展[J]. 国际病理科学与临床杂志, 2006, 26(6): 466-468</mixed-citation></ref><ref id="hanspub.24725-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Kobe, B. and Deisenhofer, J. (1993) Crystal Structure of Porcine Ribonuclease Inhibitor, a Protein with Leucine-Rich Repeats. Nature, 366, 751-756. https://doi.org/10.1038/366751a0</mixed-citation></ref><ref id="hanspub.24725-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Kobe, B. and Deisenhofer, J.A. (1995) Structural Basis of the Interactions between Leucine-Rich Repeats and Protein Ligands. Nature, 374, 183-186. https://doi.org/10.1038/374183a0</mixed-citation></ref><ref id="hanspub.24725-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Kobe, B. and Kajava, A.V. (2001) The Leucine-Rich Repeat as a Protein Recognition Motif. Current Opinion in Structural Biology, 11, 725-732. https://doi.org/10.1016/S0959-440X(01)00266-4</mixed-citation></ref><ref id="hanspub.24725-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Gunduz, M., Ouchida, M., Fukushima, K., et al. (2002) Allelic Loss and Reduced Expression of the ING3, a Candidate Tumor Suppressor Gene at 7q31, in Human Head and Neck Cancers. Oncogene, 21, 4462-4470.  
https://doi.org/10.1038/sj.onc.1205540</mixed-citation></ref><ref id="hanspub.24725-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Tan, G., Xiao, J., Tian, Y., et al. (2002) Microsatellite Analyses of Loci at 7q31.3-q36 Reveal a Minimum of Two Common Regions of Deletion in Nasopharyngeal Carcinoma. Otolaryngology—Head and Neck Surgery, 126, 296-300. https://doi.org/10.1067/mhn.2002.123046</mixed-citation></ref><ref id="hanspub.24725-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Haddad, R., Vincent, J.B., Gryfe, R., et al. (2004) Chromosome 7q31 Allelic Imbalance and Somatic Mutations of RAY1/ST7 Gene in Colorectal Cancer. Cancer Letters, 203, 87-90. https://doi.org/10.1016/j.canlet.2003.08.003</mixed-citation></ref><ref id="hanspub.24725-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Kawana, Y., Ichikawa, T., Suzaki, H., et al. (2002) Loss of Heterozygosity at 7q31.1 and 12p13-12 in Advanced Prostate Cancer. Prostate, 53, 60-64. https://doi.org/10.1002/pros.10131</mixed-citation></ref><ref id="hanspub.24725-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Zenklusen, J.C., Conti, C.J. and Green, E.D. (2001) Mutational and Functional Analyses Reveal that ST7 Is a Highly Conserved Tumor-Suppressor Gene on Human Chromosome 7q31. Nature Genetics, 27, 392-398.  
https://doi.org/10.1038/86891</mixed-citation></ref><ref id="hanspub.24725-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Chernova, O.B., Somerville, R.P. and Cowell, J.K. (1998) A Novel Gene, LGI1, from 10q24 Is Rearranged and Downregulated in Malignant Brain Tumors. Oncogene, 17, 2873-2881. https://doi.org/10.1038/sj.onc.1202481</mixed-citation></ref><ref id="hanspub.24725-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">王洁如, 钱骏, 董利, 等. 富亮氨酸重复超家族新成员LRRC4的克隆与在脑瘤中的表达分析[J]. 生物化学与生物物理进展, 2002, 29(2): 233-239.</mixed-citation></ref><ref id="hanspub.24725-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Q., Wang, J., Fan, S., et al. (2005) Expression and Functional Characterization of LRRC4, a Novel Brain-Specific Member of the LRR Superfamily. FEBS Letters, 579, 3674-3682.</mixed-citation></ref><ref id="hanspub.24725-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Wang, J.R., Li, X.L., Fan, S.Q., et al. (2003) Expression of LRRC4 Has the Potential to Decrease the Growth Rate and Tumorigenesis of Glioblastoma Cell Line U251. Chinese Journal of Cancer, 22, 897-902.</mixed-citation></ref><ref id="hanspub.24725-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">武明花, 唐运莲, 李小玲, 曹利, 李桂源. LRRC4通过LRR结构域抑制脑胶质母细胞瘤U251细胞的生长和侵袭[J]. 中国生物化学与分子生物学报, 2007, 23(8): 617-624.</mixed-citation></ref><ref id="hanspub.24725-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">陈琼, 武明花, 周艳宏, 唐运莲, 黄琛, 李小玲, 李桂源. LRRC4通过SDF-1α/CXCR4生物学轴抑制脑胶质瘤细胞侵袭迁移能力[J]. 中南大学学报(医学版), 2007, 32(5): 735-741.</mixed-citation></ref><ref id="hanspub.24725-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Krex, D., Hauses, M., Appeh, H., et al. (2002) Physical and Functional Characterization of the Human LGll Gene and Its Possible Role in Glioma Development. Acta Neuropathologica, 103, 255-266.  
https://doi.org/10.1007/s004010100463</mixed-citation></ref><ref id="hanspub.24725-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Kunapuli, P., Chitta, K.S. and Cowell, J.K. (2003) Suppression of the Cell Proli-feration and Invasion Phenotypes in Glioma Cells by the LGll Gene. Oncogene, 22, 3985-3991. https://doi.org/10.1038/sj.onc.1206584</mixed-citation></ref><ref id="hanspub.24725-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Richardson, A.L., Wang, Z.C., De Nicolo, A., et al. (2006) X Chromosomal Ab-normalities in Basal-Like Human Breast Cancer. Cancer Cell, 9, 121-132. https://doi.org/10.1016/j.ccr.2006.01.013</mixed-citation></ref><ref id="hanspub.24725-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Sun, L., Hui, A.M., Su, Q., et al. (2006) Neuronal and Glioma-Derived Stem Cell Factor Induces Angiogenesis within the Brain. Cancer Cell, 9, 287-300. https://doi.org/10.1016/j.ccr.2006.03.003</mixed-citation></ref><ref id="hanspub.24725-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Bianchini, M., Levy, E., Zucchini, C., et al. (2006) Comparative Study of Gene Expression by cDNA Microarray in Human Colorectal Cancer Tissues and Normal Mucosa. International Journal of Oncology, 29, 83-94.</mixed-citation></ref><ref id="hanspub.24725-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Lapointe, J., Li, C., Higgins, J.P., et al. (2004) Gene Expression Profiling Identifies Clinically Relevant Subtypes of Prostate Cancer. Proceedings of the National Academy of Sciences of the United States of America, 101, 811-816.  
https://doi.org/10.1073/pnas.0304146101</mixed-citation></ref><ref id="hanspub.24725-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Chen, X., Leung, S.Y., Yuen, S.T., et al. (2003) Variation in Gene Expression Patterns in Human Gastric Cancers. Molecular Biology of the Cell, 14, 3208-3230.</mixed-citation></ref><ref id="hanspub.24725-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">阚亮, 张萌, 何平. LRRC3B在非小细胞肺癌中表达下调及其与高TNM分期、淋巴结转移的相关性[J]. 中国医学前沿杂志(电子版), 2016, 8(5): 131-135.</mixed-citation></ref><ref id="hanspub.24725-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Y., Peng, Y., Zhou, Y., et al. (2014) The Clinical Value of LRRC3B Gene Expression and Promoter Hypermethylation in Breast Carci-nomas. Cell Biochemistry and Biophysics, 70, 1035-1041.  
https://doi.org/10.1007/s12013-014-0018-1</mixed-citation></ref><ref id="hanspub.24725-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">张祖萍, 武明花, 唐海林, 王蓉, 李丹, 李小玲, 李桂源. 5-Aza-CdR对胶质瘤细胞生长及LRRC4基因异常甲基化的影响[J]. 生物化学与生物物理进展, 2009, 36(7): 904-909.</mixed-citation></ref><ref id="hanspub.24725-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, J., Li, Q., Zhang, S., Xu, Q. and Wang, T. (2016) Lgr4 Promotes Prostate Tumorigenesis through the Jmjd2a/AR Signaling Pathway. Experi-mental Cell Research, 349, 77-84.</mixed-citation></ref><ref id="hanspub.24725-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Fukuma, M., Tanese, K., Effendi, K., Yamazaki, K., Masugi, Y., Suda, M., et al. (2013) Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 5 Regulates Epithelial Cell Phenotype and Survival of Hepatocellular Carcinoma Cells. Experimental Cell Research, 319, 113-121.</mixed-citation></ref><ref id="hanspub.24725-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Yamanoi, K., Fukuma, M., Uchida, H., Kushima, R., Yamazaki, K., Katai, H., et al. (2013) Overexpression of Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 5 in Gastric Cancer. Pathology International, 63, 13-19.</mixed-citation></ref><ref id="hanspub.24725-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Tanese, K., Fukuma, M., Yamada, T., Mori, T., Yoshikawa, T., Watanabe, W., et al. (2008) G-Protein-Coupled Receptor GPR49 Is Up-Regulated in Basal Cell Carcinoma and Promotes Cell Proliferation and Tumor Formation. The American Journal of Pathology, 173, 835-843.</mixed-citation></ref><ref id="hanspub.24725-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">McClanahan, T., Koseoglu, S., Smith, K., Grein, J., Gustafson, E., Black, S., et al. (2006) Identification of Overexpression of Orphan G Protein-Coupled Receptor GPR49 in Human Colon and Ovarian Primary Tumors. Cancer Biology &amp; Therapy, 5, 419-426.</mixed-citation></ref></ref-list></back></article>